Hong Kong Tests Clear Europharm Of More Gout-Drug Contaminant
This article was originally published in PharmAsia News
Hong Kong health authorities report that all of Europarm's 41 pharmaceuticals have proved devoid of the rhizopus mold so far. The tests were conducted after Europharm products containing allopurinol were ordered recalled. The drugs at issue are indicated for treating gout and were discovered by a University of Hong Kong study to be contaminated. A Department of Health spokesman said laboratory tests were continuing and final results were expected in a few days. (Click here for more
You may also be interested in...
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.